Dr. Randall Jones, Founder and CEOBreaking the status quo by revolutionizing the power of AI technology to enhance MRI interpretation is the medical imaging software company, Bot Image.
“Our solutions can easily differentiate between cancerous and noncancerous tissue and even identify pseudo cancer. This allows the healthcare community to save costs while eliminating the need for patients to undergo unnecessary biopsies, leading to possible infections and bleeding,” states Dr. Randall Jones, CEO and Founder, Bot Image.
QT Prostate MRI and ProstatID are trained with thousands of proprietary MR image sets, radiologist interpretations, segmented prostate gland image sets, pathology laboratory results, correlation data, and first-pass AI interpretations to aid early diagnosis of prostate cancer.
ProstatID and QT Prostate MRI are nearly identical in terms of functionality, the output they generate, and their base algorithms. However, they are intended for different uses, subjecting them to distinct FDA regulations.
The ProstatID is a computer-aided detection (CADe) and computer-aided diagnostic (CADx) solution aiding trained physicians in detecting prostate cancer.
Bot Image’s QT Prostate MRI is an excellent tool to check the accuracy of a read during both training and as quality oversight. It utilizes a combination of ML, random forest weighting, and biparametric MRI (bpMRI) or multiparametric MRI (mpMRI) image sets to deliver a colorized representation of both normal and abnormal tissue with accuracy. This tool can be used for the quality testing of prior interpretations, training radiology interns, and quality oversight during clinical practice.
Bot Image’s offering fits seamlessly into the radiological workflow. Once the radiologist receives the MRI images, they can be sent via the HIPAA-secure VPN to the company’s cloud-hosted server. The image sets go through quality testing and reformatting. A comprehensive report is produced within minutes—making it a real-time diagnostic tool.
Our solutions can easily differentiate between cancerous and noncancerous tissue and even identify pseudo cancer. This allows the healthcare community to save costs while eliminating the need for patients to undergo unnecessary biopsies, leading to possible infections and bleeding
“Our solution is a true lifesaver in the prostate cancer space in driving benefit for the medical and radiological community, and humanity as a whole. It is the first of its kind to get approval in the U.S. and we are submitting for the CE mark so that it can be approved in Europe and Canada,” says Dr. Jones.
Bot Image has set a new benchmark in MRI interpretation through its solution that reduces false positives and negatives. This has been possible primarily due to Dr. Jones’s drive toward innovation and willingness to push the envelope of imaging technology—building on his unique blend of training, industry experience, and entrepreneurship. With this prowess, Dr. Jones wishes to enhance Bot Image’s capability by exploring other cancer detection methods in human anatomy via the company’s patent-pending software that is easy to use, offers connectivity, and is affordable.
“Bot Image is considered a healthcare disruptor because our novel technologies can lead to significant improvement in the healthcare delivery process and outcome,” states Dr. Jones.
